Bethany Rae O'Hollaren, MD
Family Practice · Hillsboro
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 2 carriers
- Office
- 1
- Since medical school
- 11 years
- Oregon Health Sciences University School of Medicine, 2015
Offices
1 location · Neighborhood Health Center · 35 clinicians in this group
Looking this up.
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
5 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. O'Hollaren’s office at (503) 848-5861 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A147987 · Current
Licensed to practise in California · since 2017 · expires 2026-12-31 · Oregon Health & Science University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Family Medicine - Family Medicine
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Medicaid work
$212,602 in 2024
Medicaid paid $212,602 for 4,214 billed services this clinician did in 2024, up to 65 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 334 | $211,433 |
| Return visit (30+ min) | 519 | $589 |
| Short return visit (20+ min) | 369 | $397 |
| Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 54 | $136 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 173 | $46 |
| Pain severity quantified; no pain present (COA) (ONC) | 222 | $0 |
| Medication list documented in medical record (COA) | 473 | $0 |
| Review of all medications by a prescribing practitioner or clinical pharmacist (such as, prescriptions, OTCs, herbal therapies and supplements) documented in the medical record (COA) | 252 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 671 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 190 | $0 |
| Most recent systolic blood pressure greater than or equal to 140 mm Hg (HTN, CKD, CAD) (DM) | 46 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 791 | $0 |
| 2024 | 4,214 | 13 | 65 | $212,602 |
| 2023 | 1,158 | 9 | 61 | $109,514 |
| 2022 | 1,293 | 9 | 46 | $147,456 |
| 2021 | 3,501 | 13 | 152 | $539,862 |
| 2020 | 3,149 | 10 | 159 | $282,753 |
| 2019 | 2,473 | 5 | 162 | $308,347 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 179 | $108,686 |
| Return visit (30+ min) | 301 | $473 |
| Short return visit (20+ min) | 176 | $335 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 129 | $15 |
| Albumin; urine (eg, microalbumin), quantitative | 13 | $5 |
| Most recent hemoglobin A1c (HbA1c) level less than 7.0% (DM) | 17 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 148 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 176 | $0 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 19 | $0 |
2022
| Clinic visit/encounter, all-inclusive | 245 | $146,201 |
| Return visit (30+ min) | 268 | $602 |
| Short return visit (20+ min) | 351 | $463 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 72 | $140 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 172 | $50 |
| Most recent hemoglobin A1c (HbA1c) level less than 7.0% (DM) | 20 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 57 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 95 | $0 |
| Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use | 13 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 1,105 | $536,807 |
| Short return visit (20+ min) | 1,243 | $1,236 |
| Hemoglobin A1C level | 56 | $616 |
| Short return visit | 379 | $612 |
| Blood test, lipids (cholesterol and triglycerides) | 25 | $380 |
| Return visit (30+ min) | 226 | $203 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 26 | $10 |
| Most recent hemoglobin A1c (HbA1c) level less than 7.0% (DM) | 58 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 129 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 38 | $0 |
| Most recent systolic blood pressure greater than or equal to 140 mm Hg (HTN, CKD, CAD) (DM) | 30 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 146 | $0 |
2020
| Clinic visit/encounter, all-inclusive | 1,183 | $279,312 |
| Short return visit (20+ min) | 1,335 | $1,622 |
| Payment for communication technology-based services for 5 minutes or more of a virtual (non-face-to-face) communication between an rural health clinic (rhc) or federally qualified health center (fqhc) practitioner and rhc or fqhc patient, or 5 minutes or more of remote evaluation of recorded video and/or images by an rhc or fqhc practitioner, occurring in lieu of an office visit; rhc or fqhc only | 179 | $1,485 |
| Short return visit | 164 | $158 |
| Return visit (30+ min) | 84 | $123 |
| Creatinine; blood | 17 | $47 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 47 | $5 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 46 | $0 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | 47 | $0 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 11-20 minutes of medical discussion | 47 | $0 |
2019
| Clinic visit/encounter, all-inclusive | 1,203 | $305,009 |
| Short return visit (20+ min) | 1,067 | $2,450 |
| Return visit (30+ min) | 139 | $695 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 49 | $188 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 15 | $5 |
Drugs they prescribed that Part D paid
$87,712
Pharmacies billed $87,712 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 3% of their Part D prescriptions (21 of 772) in 2024. Above the middle of the specialty; the typical family practice clinician is at 2%. Long-acting opioids: 81% of their opioid prescriptions.
633 generic and fewer than 11 brand-name prescriptions · $87,712 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ozempic | 16 | $13,957 | $872 |
| Buprenorphine | 11 | $3,074 | $279 |
| Basaglar Kwikpen U-100 | 12 | $2,265 | $189 |
| Albuterol Sulfate Hfa | 31 | $1,110 | $36 |
| Clotrimazole | 26 | $790 | $30 |
See all 21 drugs
| Ozempic | 16 | $13,957 | $872 |
| Buprenorphine | 11 | $3,074 | $279 |
| Basaglar Kwikpen U-100 | 12 | $2,265 | $189 |
| Albuterol Sulfate Hfa | 31 | $1,110 | $36 |
| Clotrimazole | 26 | $790 | $30 |
| Levothyroxine | 30 | $381 | $13 |
| Atorvastatin | 60 | $338 | $6 |
| Amlodipine Besylate | 47 | $264 | $6 |
| Gabapentin | 26 | $225 | $9 |
| Glipizide | 15 | $159 | $11 |
| Metformin | 19 | $141 | $7 |
| Famotidine | 16 | $107 | $7 |
| Omeprazole | 17 | $102 | $6 |
| Diclofenac | 12 | $87 | $7 |
| Fluticasone Propionate | 14 | $83 | $6 |
| Lisinopril | 13 | $76 | $6 |
| Pregabalin | 11 | $66 | $6 |
| Trazodone | 15 | $60 | $4 |
| Alendronate | 11 | $50 | $5 |
| Cyclobenzaprine | 18 | $27 | $2 |
| Hydrochlorothiazide | 15 | $27 | $2 |
Year by year
| 2024 | 772 | 97 | 3% (21) | None | $87,712 |
| 2023 | 529 | 70 | 3% (17) | None | $50,382 |
| 2022 | 452 | 63 | None | None | $38,656 |
| 2021 | 876 | 145 | 2% (16) | 20% | $88,672 |
| 2020 | 780 | 104 | 2% (14) | None | $52,873 |
| 2019 | 417 | 134 | 0% (0) | None | $28,179 |
| 2018 | 482 | 45 | None | 17% | $45,206 |
| 2017 | 558 | 53 | None | 15% | $27,642 |
| 2016 | 347 | 54 | 0% (0) | None | $20,501 |
| 2015 | 53 | None | 0% (0) | None | $4,935 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 16 drugs
| Atorvastatin | 63 | $1,493 | $24 |
| Clotrimazole | 18 | $878 | $49 |
| Gabapentin | 19 | $786 | $41 |
| Albuterol Sulfate Hfa | 14 | $657 | $47 |
| Glipizide | 19 | $563 | $30 |
| Levothyroxine | 24 | $550 | $23 |
| Losartan | 19 | $495 | $26 |
| Atenolol | 16 | $203 | $13 |
| Metformin | 17 | $194 | $11 |
| Hydrochlorothiazide | 12 | $169 | $14 |
| Lisinopril | 13 | $168 | $13 |
| Amlodipine Besylate | 26 | $162 | $6 |
| Omeprazole | 14 | $154 | $11 |
| Hydroxyzine | 11 | $132 | $12 |
| Famotidine | 12 | $107 | $9 |
| Fluticasone Propionate | 11 | $86 | $8 |
2022: 9 drugs
| Atorvastatin | 49 | $775 | $16 |
| Levothyroxine | 23 | $490 | $21 |
| Glipizide | 22 | $348 | $16 |
| Losartan | 17 | $270 | $16 |
| Amlodipine Besylate | 34 | $225 | $7 |
| Lisinopril | 19 | $202 | $11 |
| Carvedilol | 11 | $187 | $17 |
| Gabapentin | 24 | $186 | $8 |
| Metformin | 14 | $111 | $8 |
2021: 26 drugs
| Januvia | 17 | $13,217 | $777 |
| Trulicity | 12 | $9,844 | $820 |
| Lantus Solostar | 12 | $3,559 | $297 |
| Atorvastatin | 72 | $1,183 | $16 |
| Levothyroxine | 26 | $572 | $22 |
| Albuterol Sulfate Hfa | 11 | $492 | $45 |
| Glipizide | 28 | $341 | $12 |
| Losartan | 25 | $331 | $13 |
| Carvedilol | 20 | $309 | $15 |
| Amlodipine Besylate | 43 | $295 | $7 |
| Gabapentin | 30 | $238 | $8 |
| Omeprazole | 14 | $208 | $15 |
| Clopidogrel | 12 | $175 | $15 |
| Fluticasone Propionate | 18 | $167 | $9 |
| Benazepril | 13 | $162 | $12 |
| Metformin | 20 | $156 | $8 |
| Trazodone | 12 | $127 | $11 |
| Acetaminophen-Codeine | 12 | $125 | $10 |
| Lisinopril | 26 | $101 | $4 |
| Hydrochlorothiazide | 14 | $89 | $6 |
| Pantoprazole | 11 | $87 | $8 |
| Cephalexin | 11 | $63 | $6 |
| Lamotrigine | 12 | $51 | $4 |
| Hydroxyzine | 12 | $45 | $4 |
| Furosemide | 17 | $44 | $3 |
| Fluoxetine | 11 | $29 | $3 |
2020: 20 drugs
| Atorvastatin | 73 | $1,112 | $15 |
| Levothyroxine | 32 | $829 | $26 |
| Carbamazepine | 13 | $690 | $53 |
| Amlodipine Besylate | 55 | $440 | $8 |
| Losartan | 21 | $315 | $15 |
| Rosuvastatin | 12 | $280 | $23 |
| Gabapentin | 22 | $243 | $11 |
| Lisinopril | 33 | $242 | $7 |
| Carvedilol | 22 | $213 | $10 |
| Fluticasone Propionate | 22 | $199 | $9 |
| Hydrochlorothiazide | 23 | $166 | $7 |
| Trazodone | 14 | $159 | $11 |
| Metformin | 18 | $143 | $8 |
| Furosemide | 22 | $111 | $5 |
| Clopidogrel | 13 | $102 | $8 |
| Hydroxyzine | 14 | $84 | $6 |
| Baclofen | 11 | $83 | $8 |
| Omeprazole | 12 | $77 | $6 |
| Metoprolol | 11 | $71 | $6 |
| Fluoxetine | 17 | $38 | $2 |
2019: 8 drugs
| Atorvastatin | 22 | $346 | $16 |
| Amlodipine Besylate | 22 | $190 | $9 |
| Fluticasone Propionate | 13 | $163 | $13 |
| Metformin | 19 | $124 | $7 |
| Losartan | 18 | $106 | $6 |
| Lisinopril | 14 | $92 | $7 |
| Omeprazole | 13 | $77 | $6 |
| Furosemide | 14 | $68 | $5 |
2018: 16 drugs
| Humalog | 11 | $9,684 | $880 |
| Atorvastatin | 51 | $654 | $13 |
| Ventolin Hfa | 11 | $647 | $59 |
| Flecainide Acetate | 11 | $432 | $39 |
| Divalproex | 12 | $300 | $25 |
| Omeprazole | 32 | $227 | $7 |
| Fluticasone Propionate | 12 | $198 | $16 |
| Warfarin | 19 | $180 | $9 |
| Sertraline | 19 | $159 | $8 |
| Metformin | 31 | $147 | $5 |
| Duloxetine | 11 | $124 | $11 |
| Sucralfate | 11 | $117 | $11 |
| Lisinopril | 14 | $63 | $5 |
| Losartan-Hydrochlorothiazide | 11 | $58 | $5 |
| Amlodipine Besylate | 18 | $46 | $3 |
| Hydrochlorothiazide | 12 | $12 | $1 |
2017: 16 drugs
| Advair Diskus | 12 | $4,471 | $373 |
| Haloperidol | 12 | $814 | $68 |
| Atorvastatin | 54 | $672 | $12 |
| Flecainide Acetate | 12 | $468 | $39 |
| Omeprazole | 47 | $364 | $8 |
| Sertraline | 27 | $251 | $9 |
| Metformin | 35 | $205 | $6 |
| Levothyroxine | 15 | $186 | $12 |
| Warfarin | 19 | $181 | $10 |
| Alendronate | 23 | $176 | $8 |
| Duloxetine | 11 | $154 | $14 |
| Lisinopril | 25 | $140 | $6 |
| Gabapentin | 18 | $97 | $5 |
| Amlodipine Besylate | 17 | $67 | $4 |
| Losartan-Hydrochlorothiazide | 12 | $65 | $5 |
| Hydrochlorothiazide | 16 | $21 | $1 |
2016: 11 drugs
| Advair Diskus | 12 | $4,219 | $352 |
| Atorvastatin | 23 | $377 | $16 |
| Levothyroxine | 24 | $227 | $9 |
| Alendronate | 20 | $190 | $10 |
| Omeprazole | 21 | $163 | $8 |
| Ramipril | 11 | $143 | $13 |
| Sertraline | 16 | $56 | $4 |
| Furosemide | 16 | $54 | $3 |
| Metformin | 14 | $44 | $3 |
| Lisinopril | 12 | $27 | $2 |
| Amlodipine Besylate | 11 | $26 | $2 |
Professional record
- NPI
- 1821438631
- Licence
- CA A147987California A147987: Current · expires 2026-12-31
- Trained
- Oregon Health Sciences University School of Medicine, 2015 · 11 years ago
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Family medicine (207Q00000X); Student in a training program (390200000X)
- Mailing address
- 7320 Sw Hunziker Rd Ste 300, Portland, OR, 97223
- NPI first listed
- 2013-06-26
- NPI last updated
- 2026-03-14
- NPI record certified
- 2026-03-14
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 777 E Santa Clara St, San Jose, CA, 95112
This office lists an electronic records connection.